Fas promoter -670 polymorphism and the risk of cervical cancer: A case-control study in multi-ethnic Malaysia

Abstract

Background/Objective: Single nucleotide polymorphism (SNP) is a commonly occurring DNA sequence variation within the human population. The prevalence of these sequence variations differs in various populations and may lead to the suboptimal regulation of genes, including those of the apoptosis pathway. The regulation of cellular death is partially controlled by the interaction between tumor necrosis factor receptor family gene, Fas and its ligand, FasL. A base substitution in Fas -670 A>G (rs1800682) has been found to alter the binding affinity of the Fas protein to its activators, potentially altering its apoptotic potential. The lack of proper apoptosis regulation can lead to a wide plethora of human conditions involving uncontrolled cellular growth such as cancer. The purpose of the study was to investigate whether there was any association between the Fas -670 polymorphism and risk of cervical cancer in multi-ethnic Malaysian women.

Methods: Using restriction fragment length polymorphism (RFLP-PCR), Chi-square and logistic regression analysis, this study investigated the Fas -670 SNP and its associations with cervical cancer in the multi-ethnic population of Malaysia.

Results: No significant associations were found between Fas -670 A>G SNP and risk of cervical cancer using the genotype model, dominant model and allele frequency model analysis, even after stratification into the Malay, Chinese and Indian ethnic subgroups; and cancer types.

Conclusion: Our results showed that the A>G SNP of Fas -670 does not affect the risk of cervical carcinogenesis in Malaysian females.

Keywords

Fas / SNP / rs1800682 / Cervical cancer / Malaysia

References

[1] Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995; 267(5203): 1456-62. PMid: 7878464. https://doi.org/10.1126/science.7878464

[2] Budihardjo I, Oliver H, Lutter M, et al. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999; 15: 269-90. PMid: 10611963. https://doi.org/10.1146/annurev.cellbio.15.1.269

[3] Mor G, Straszewski S, Kamsteeg M. Role of the Fas/Fas ligand system in female reproductive organs: survival and apoptosis. Biochem Pharmacol. 2002; 64(9): 1305-15. PMid: 12392813. https://doi.org/10.1016/S0006-2952(02)01267-4

[4] Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis. 2004; 9(6): 691-704. PMid: 15505412. https://doi.org/10.1023/B:APPT.0000045786.98031.1d

[5] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359-86. PMid: 25220842. https://doi.org/10.1002/ijc.29210

[6] Azizah AM, Nor Saleha IT, Noor Hashimah A, et al. Malaysian National Cancer Registry Report 2007-2011 [Internet]. 2016 [cited 2017 Aug 14]: 50-2. Available from: http://nci.moh.gov.my/index.php/ms/main-menu-2/laporan

[7] zur Hausen H, de Villiers EM. Human papillomaviruses. Annu Rev Microbiol. 1994; 48: 427-47. PMid: 7826013. https://doi.org/10.1146/annurev.mi.48.100194.002235

[8] Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1): 12-9. PMid: 10451482. https://doi.org/10.1002/(SICI)1096-9896(199909)189:13.0.CO;2-F

[9] Barbisan G, Contreras A, Perez LO, et al. The effect of TP53 codon 72 and RNASEL codon 462 polymorphisms on the development of cervical cancer in Argentine women. Cancer Genetics. 2011; 204(5): 270-7. PMid: 21665181. https://doi.org/10.1016/j.cancergen.2011.04.001

[10] Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991; 66(2): 233-43. PMid: 1713127. https://doi.org/10.1016/0092-8674(91)90614-5

[11] Nagata S, Golstein P. The Fas death factor. Science. 1995; 267(5203): 1449-56. PMid: 7533326. https://doi.org/10.1126/science.7533326

[12] Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993; 75(6): 1169-78. PMid: 7505205. https://doi.org/10.1016/0092-8674(93)90326-L

[13] Ando K, Hiroishi K, Kaneko T, et al. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol. 1997; 158(11): 5283-91. PMid: 9164947.

[14] Zamai L, Ahmad M, Bennett IM, et al. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998; 188(12): 2375-80. PMid: 9858524. https://doi.org/10.1084/jem.188.12.2375

[15] Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993; 69(4): 415-29. PMid: 7693996.

[16] Hougardy BM, van der Zee AG, van den Heuvel FA, et al. Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid. Gynecol Oncol. 2005; 97(2): 353-64. PMid: 15863130. https://doi.org/10.1016/j.ygyno.2005.01.036

[17] Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997; 34(8-9): 577-82. PMid: 9393960. https://doi.org/10.1016/S0161-5890(97)00081-3

[18] Sibley K, Rollinson S, Allan JM, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003; 63(15): 4327-30. PMid: 12907599.

[19] Schindler C, Darnell JE, Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995; 64: 621-51. PMid: 7574495. https://doi.org/10.1146/annurev.bi.64.070195.003201

[20] Kanemitsu S, Ihara K, Saifddin A, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol. 2002; 29(6): 1183-8. PMid: 12064832.

[21] Xu X, Fu XY, Plate J, et al. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 1998; 58(13): 2832-7. PMid: 9661898.

[22] Stegh AH, Schickling O, Ehret A, et al. DEDD, a novel death effector domain-containing protein, targeted to the nucleolus. EMBO J. 1998; 17(20): 5974-86. PMid: 9774341. https://doi.org/10.1093/emboj/17.20.5974

[23] Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995; 14(22): 5579-88. PMid: 8521815.

[24] Muzio M, Salvesen GS, Dixit VM. FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J Biol Chem. 1997; 272(5): 2952-6. PMid: 9006941. https://doi.org/10.1074/jbc.272.5.2952

[25] Scaffidi C, Kischkel FC, Krammer PH, et al. Analysis of the CD95 (APO-1/Fas) death-inducing signaling complex by high-resolution two-dimensional gel electrophoresis. Methods Enzymol. 2000; 322: 363-73. PMid: 10914030. https://doi.org/10.1016/S0076-6879(00)22033-8

[26] Scaffidi C, Kirchhoff S, Krammer PH, et al. Apoptosis signaling in lymphocytes. Curr Opin Immunol. 1999; 11(3): 277-85. PMid: 10375553. https://doi.org/10.1016/S0952-7915(99)80045-4

[27] Chatterjee K, Engelmark M, Gyllensten U, et al. Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes. 2009; 2: 238. PMid: 19941645. https://doi.org/10.1186/1756-0500-2-238

[28] Li H, Guo HY, Sun T, et al. [Association between Fas/Fas L genes promoter polymorphisms and pathogenic risk of cervical cancer]. Zhonghua Zhong Liu Za Zhi. 2009; 31(1): 38-41. PMid: 19538867.

[29] Sun T, Zhou Y, Li H, et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005; 202(7): 967-74. PMid: 16186185. https://doi.org/10.1084/jem.20050707

[30] Kang S, Dong SM, Seo SS, et al. FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet. 2008; 180(1): 1-5. PMid: 18068525. https://doi.org/10.1016/j.cancergencyto.2007.09.002

[31] Engelmark MT, Renkema KY, Gyllensten UB. No evidence of the involvement of the Fas -670 promoter polymorphism in cervical cancer in situ. Int J Cancer. 2004; 112(6): 1084-5. PMid: 15316939. https://doi.org/10.1002/ijc.20515

[32] Chen X, Mo W, Peng Q, et al. Lack of association between Fas rs 180082 polymorphism and risk of cervical cancer: an update by meta-analysis. BMC Med Genet. 2013; 14: 71. PMid: 23865866. https://doi.org/10.1186/1471-2350-14-71

[33] Shen J, Sun NX. Association between FAS A670G polymorphism and susceptibility to cervical cancer: evidence from a meta-analysis. Tumour Biol. 2013; 34(6): 3443-8. PMid: 23900676. https://doi.org/10.1007/s13277-013-0920-y

[34] Ueda M, Terai Y, Kanda K, et al. Fas gene promoter -670 polymorphism in gynecological cancer. Int J Gynecol Cancer. 2006; 16 Suppl 1: 179-82. PMid: 16515587. https://doi.org/10.1111/j.1525-1438.2006.00505.x

[35] Kordi Tamandani DM, Sobti RC, Shekari M. Association of Fas-670 gene polymorphism with risk of cervical cancer in North Indian population. Clin Exp Obstet Gynecol. 2008; 35(3): 183-6. PMid: 18754288.

[36] Zucchi F, da Silva ID, Ribalta JC, et al. Fas/CD 95 promoter polymorphism gene and its relationship with cervical carcinoma. Eur J Gynaecol Oncol. 2009; 30(2): 142-4. PMid: 19480241.

[37] Lai HC, Lin WY, Lin YW, et al. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol Oncol. 2005; 99(1): 113-8. PMid: 15996722. https://doi.org/10.1016/j.ygyno.2005.05.010

[38] Lai HC, Sytwu HK, Sun CA, et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer. 2003; 103(2): 221-5. PMid: 12455036. https://doi.org/10.1002/ijc.10800

[39] Rudert F, Visser E, Forbes L, et al. Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/APO-1) gene. DNA Cell Biol. 1995; 14(11): 931-7. PMid: 7576179. https://doi.org/10.1089/dna.1995.14.931

[40] Look DC, Pelletier MR, Tidwell RM, et al. Stat 1 depends on transcriptional synergy with Sp1. J Biol Chem. 1995; 270(51): 30264-7. PMid: 8530443. https://doi.org/10.1074/jbc.270.51.30264

[41] Li Y, Hao YL, Kang S, et al. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes. Gynecol Oncol. 2013; 128(3): 584-9. PMid: 23234803. https://doi.org/10.1016/j.ygyno.2012.12.002

[42] Wu J, Metz C, Xu X, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003; 170(1): 132-8. PMid: 12496392. https://doi.org/10.4049/jimmunol.170.1.132

[43] Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD 95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med. 1996; 2(12): 1361-6. PMid: 8946836. https://doi.org/10.1038/nm1296-1361

[44] Louie KS, de Sanjose S, Diaz M, et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer. 2009; 100(7): 1191-7. PMid: 19277042. https://doi.org/10.1038/sj.bjc.6604974

[45] Munoz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet. 2002; 359(9312): 1093-101. PMid: 11943256. https://doi.org/10.1016/S0140-6736(02)08151-5

[46] Sikstrom B, Hellberg D, Nilsson S, et al. Smoking, alcohol, sexual behaviour and drug use in women with cervical human papillomavirus infection. Arch Gynecol Obstet. 1995; 256(3): 131-7. PMid: 7574905. https://doi.org/10.1007/BF01314641

[47] Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003; 361(9364): 1159-67. PMid: 12686037. https://doi.org/10.1016/S0140-6736(03)12949-2

[48] Wang LE, Cheng L, Spitz MR, et al. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer. 2003; 42(1): 1-8. PMid: 14512182. https://doi.org/10.1016/S0169-5002(03)00276-9